What is HC Wainwright’s Forecast for Pharvaris Q3 Earnings?

Pharvaris N.V. (NASDAQ:PHVS) – Equities researchers at HC Wainwright boosted their Q3 2025 earnings per share (EPS) estimates for shares of Pharvaris in a report released on Tuesday, November 11th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($0.68) per share for the quarter, up from their previous forecast of ($0.69). HC Wainwright currently has a “Buy” rating and a $60.00 price target on the stock. The consensus estimate for Pharvaris’ current full-year earnings is ($2.71) per share. HC Wainwright also issued estimates for Pharvaris’ Q4 2025 earnings at ($0.70) EPS, FY2025 earnings at ($3.28) EPS, Q2 2026 earnings at ($0.82) EPS, Q4 2026 earnings at ($0.90) EPS, FY2026 earnings at ($3.38) EPS and FY2027 earnings at ($2.64) EPS.

A number of other research firms have also weighed in on PHVS. Wedbush boosted their price objective on shares of Pharvaris from $27.00 to $30.00 and gave the company an “outperform” rating in a research report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research note on Wednesday, October 8th. JMP Securities reduced their price target on Pharvaris from $55.00 to $52.00 and set a “market outperform” rating on the stock in a research note on Wednesday, August 13th. Bank of America upgraded Pharvaris from an “underperform” rating to a “neutral” rating and raised their price objective for the stock from $16.00 to $27.00 in a report on Thursday, October 9th. Finally, Morgan Stanley lifted their price objective on Pharvaris from $34.00 to $37.00 and gave the company an “overweight” rating in a research report on Friday. Six investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $37.57.

Pharvaris Stock Down 2.9%

PHVS opened at $23.55 on Thursday. The firm has a market cap of $1.23 billion, a P/E ratio of -7.34 and a beta of -2.78. The business’s fifty day simple moving average is $23.20 and its 200 day simple moving average is $20.65. Pharvaris has a 52 week low of $11.51 and a 52 week high of $26.33.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.70) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.08.

Institutional Trading of Pharvaris

Institutional investors and hedge funds have recently made changes to their positions in the company. General Atlantic L.P. raised its position in shares of Pharvaris by 6.6% in the 3rd quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock worth $200,380,000 after buying an additional 500,000 shares during the period. Deerfield Management Company L.P. increased its stake in Pharvaris by 21.1% during the third quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock worth $60,939,000 after acquiring an additional 425,000 shares during the last quarter. Wellington Management Group LLP purchased a new position in shares of Pharvaris in the 3rd quarter worth about $43,282,000. Balyasny Asset Management L.P. purchased a new position in shares of Pharvaris in the 3rd quarter worth about $15,613,000. Finally, Patient Square Capital LP lifted its stake in shares of Pharvaris by 41.4% in the 3rd quarter. Patient Square Capital LP now owns 345,381 shares of the company’s stock valued at $8,617,000 after purchasing an additional 101,098 shares in the last quarter.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.